Qiagen (QGEN) Q3 2025 earnings summary

Executive summary

• Q3 2025 net sales reached $533 million, up 6% year-over-year, with adjusted EPS of $0.61, both exceeding guidance and marking the 24th consecutive quarter meeting or exceeding targets.

• Core sales grew 6% CER, led by Diagnostic solutions (QuantiFERON and QIAstat-Dx up 11% CER) and Sample technologies up 3% CER.

• Announced acquisition of Parse Biosciences for $225 million, expanding into the AI-driven single-cell market, and a $500 million synthetic share repurchase to be completed in January 2026.

• Leadership transition underway, with CEO Thierry Bernard preparing for succession.

Financial highlights

• Net sales rose 6% year-over-year to $533 million; core sales up 6% CER.

• Adjusted diluted EPS was $0.61, above the outlook of at least $0.58.

• Adjusted operating income margin steady at 29.6% of sales, absorbing currency and tariff headwinds.

• Operating cash flow for the first nine months was $466 million, including $45 million in restructuring payments.

• Free cash flow was $336 million, down 8% year-over-year due to higher IT investments and restructuring.

Outlook and guidance

• Raised adjusted EPS target for 2025 to about $2.38 CER, up from initial guidance.

• Reaffirmed net sales growth outlook of 4%-5% CER for 2025; core portfolio expected to grow 5%-6% CER.

• Q4 2025 net sales expected to be steady at CER versus Q4 2024, with adjusted EPS for Q4 expected at $0.60 CER.

• Tariffs expected to create a 90 basis point headwind on adjusted cost margin for 2025.

• Parse acquisition expected to add about $40 million in sales in 2026, initially dilutive to EPS by $0.04, accretive from 2028.